Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 10/13/2017 |
| Start Date: | November 2005 |
| End Date: | August 2015 |
Clinical Implementation and Evaluation of MR Spectroscopy for Breast Cancer Detection
Magnetic Resonance Spectroscopy (MRS) is a novel imaging technique for noninvasive probing of
biochemical properties of tissue. While MRS does not generate images of tumor per se it
allows biochemical spectroscopic data to be obtained in vivo from user defined
region-of-interest. In this manner, biochemical information elucidated by MRS can be
interpreted in relation to detailed anatomy and images of metabolite distribution can be
created. The aim of MRS is to identify presence and concentration of metabolites
characteristic for normal and abnormal (tumor) cellular activities hence allow differential
normal tissue from pathological tissue, as well as allow differentiating malignant from
benign tumors.
biochemical properties of tissue. While MRS does not generate images of tumor per se it
allows biochemical spectroscopic data to be obtained in vivo from user defined
region-of-interest. In this manner, biochemical information elucidated by MRS can be
interpreted in relation to detailed anatomy and images of metabolite distribution can be
created. The aim of MRS is to identify presence and concentration of metabolites
characteristic for normal and abnormal (tumor) cellular activities hence allow differential
normal tissue from pathological tissue, as well as allow differentiating malignant from
benign tumors.
Recent in vivo studies have reported successful use of 1H and 31P MRS in differentiating
between benign and malignant tumors in breast tissue. These studies demonstrated an increase
in the choline metabolite peak that reflects an increase in choline-containing metabolites in
70-80% of breast carcinomas, as compared to 14-18% of benign breast tumors.The objectives
would be to determine sensitivity/specificity of MRS in the context of breast CA, We will use
normal volunteers to test software and to develop and optimize MR scan sequences prior to or
during the testing of target subjects with suspicious breast lesion.
between benign and malignant tumors in breast tissue. These studies demonstrated an increase
in the choline metabolite peak that reflects an increase in choline-containing metabolites in
70-80% of breast carcinomas, as compared to 14-18% of benign breast tumors.The objectives
would be to determine sensitivity/specificity of MRS in the context of breast CA, We will use
normal volunteers to test software and to develop and optimize MR scan sequences prior to or
during the testing of target subjects with suspicious breast lesion.
Inclusion Criteria:
- subjects should have well defined suspicious breast lesion and that will be biopsied
- subjects are to include; varied volunteers with different breast tissue with
characteristics such as dense breasts, fibrocystic breasts, "small" breasted and
"large" breasted women.
Exclusion Criteria:
- Women of childbearing potential who are not practicing a medically accepted method of
birth control should not participate
- Subjects that are pregnant, breast-feeding, should not be able to participate
- Subjects having any of the following metallic devices, will be ineligible to
participate in the study: pacemaker, prosthesis, artificial heart valve, coronary
artery stents, TENS (Transcutaneous electric nerve stimulator) or other neurological
stimulation units and surgical clips.
We found this trial at
1
site
Click here to add this to my saved trials
